DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» CD38
CD38
CD38, CD157, and RAGE As Molecular Determinants for Social Behavior
Dysregulated CD38 Expression on Peripheral Blood Immune Cell Subsets in SLE
CD Markers Are Routinely Used for the Immunophenotyping of Cells
The Enzymatic Activities of CD38 Enhance CLL Growth and Trafficking
Monoclonal Antibodies in Myeloma
A Molecular Signature of Dormancy in CD34+CD38- Acute Myeloid Leukaemia Cells
ADP-Ribose Or Cyclic ADP-Ribose Independently of Enzymatically
The Functional in Vitro Response to CD40 Ligation Reflects a Different
Myeloma NK Cells Are Exhausted and Have Impaired Regulation of Activation
In Vivo Evaluation of CD38 and CD138 As Targets for Nanoparticle-Based
Immunohistochemical Characteristics Of
Multi-Antigen Imaging Reveals Inflammatory DC, ADAM17
Clinical and Biological Significance of Surface Molecules in Myeloma
Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib In
The CD38 Lymphocyte Differentiation Review Marker: New Insight Into Its Ectoenzymatic Activity and Its Role As a Signal Transducer
Early KLRG1+ but Not CD57+CD8+ T Cells in Primary Cytomegalovirus Infection Predict Effector Function and Viral Control
Syndecan-1 (CD138) Immunoreactivity in Bone Marrow Biopsies of Multiple Myeloma: Shed Syndecan-1 Accumulates in Fibrotic Regions Ilene B
Hematopoietic Stem Cell & Lineage-Specific Markers
Top View
CD38/CD31 Interactions Activate Genetic Pathways Leading to Proliferation and Migration in Chronic Lymphocytic Leukemia Cells
And Memory Response Post-Germinal Center B Cell
CD38 Expression Levels in Chronic Lymphocytic Leukemia B Cells Are Associated with Activation Marker Expression and Differential Responses to Interferon Stimulation
CD38, CD81 and BAFFR Combined Expression by Transitional B Cells Distinguishes Active from Inactive Systemic Lupus Erythematosus
Roles of CD38 in the Immune Response to Infection
CD38 Ligation Induces Tyrosine Phosphorylation of Bruton
Predictive Biomarkers with Isatuximab Plus Pomalidomide and Dexamethasone in Relapsed/ Refractory Multiple Myeloma Paul G
Is There a Future for Anti-CD38 Antibody Therapy in Systemic Autoimmune Diseases?
Human B Cell to Plasma Cell Differentiation Preplasmablast
Pre-Clinical Evaluation of CD38 Chimeric Antigen Receptor Engineered T Cellsfor the Treatment of Multiple Myeloma
ALTERATION of INTRACELLULAR CALCIUM RELEASE MEDIATED by CD38 UNDER CHRONIC HYPOXIA in PULMONARY ARTERIAL SMOOTH MUSCLE CELL by S
(ADP-Ribosyl Cyclase) Is a Counter-Receptor of CD31, an Ig Superfamily Member
Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: the Multiple Myeloma Model
Bi38-3 Is a Novel CD38/CD3 Bispecific T-Cell Engager with Low Toxicity For
Characterization of Differentiation and Prognostic Biomarkers on Cd8+ Tumor-Infiltrating Lymphocytes in Metastatic Melanoma
The Mechanism of Action of the Anti-CD38 Monoclonal Antibody
Hematological Tumors of Multiple Myeloma and Other CD38
DPP8 Is a Novel Therapeutic Target for Multiple Myeloma